THERAPEUTIC EFFECT OF COMBINED TREATMENT WITH VICARABINE MONOPHOSPHATE AND IMMUN-OMODULATORS IN CHRONIC HEPATITIS B

您当前的位置：

首页 >

文章列表页 >

THERAPEUTIC EFFECT OF COMBINED TREATMENT WITH VICARABINE MONOPHOSPHATE AND IMMUN-OMODULATORS IN CHRONIC HEPATITIS B

更新时间：2024-01-17

- THERAPEUTIC EFFECT OF COMBINED TREATMENT WITH VICARABINE MONOPHOSPHATE AND IMMUN-OMODULATORS IN CHRONIC HEPATITIS B
- Journal of Chongqing Medical University Issue 3, (1996)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R512.620.5
- Published：1996，
扫描看全文
[1]黄文祥,刘之龙,王其南,盛家琦.单磷酸阿糖腺苷加免疫调节剂治疗慢性乙型肝炎临床疗效观察[J].重庆医科大学学报,1996(03):219-222.

THERAPEUTIC EFFECT OF COMBINED TREATMENT WITH VICARABINE MONOPHOSPHATE AND IMMUN-OMODULATORS IN CHRONIC HEPATITIS B. [J]. Journal of Chongqing Medical University (3).(1996)
[1]黄文祥,刘之龙,王其南,盛家琦.单磷酸阿糖腺苷加免疫调节剂治疗慢性乙型肝炎临床疗效观察[J].重庆医科大学学报,1996(03):219-222. DOI：

THERAPEUTIC EFFECT OF COMBINED TREATMENT WITH VICARABINE MONOPHOSPHATE AND IMMUN-OMODULATORS IN CHRONIC HEPATITIS B. [J]. Journal of Chongqing Medical University (3).(1996) DOI：

摘要

对９０例慢性乙型肝炎进行治疗和随访。治疗Ⅰ组为Ａｒａ—ＡＭＰ＋胸腺素；治疗Ⅱ组为Ａｒａ—ＡＭＰ＋乙肝疫苗；第Ⅲ组为对照组。治疗结束及治疗结束３个月时ＨＢｅＡｇ阴转率：治疗Ⅰ组为４０％为４２％：治疗Ⅱ组为３６．７％和４８％；对照组为１３．３％和１２％。ＨＢＶ—ＤＮＡ阴转辜分别为４６．１％和５５．８％，４８％和５６％及２０％和２４的。与对照组相比，两个治疗组ＨＢｅＡｇ和ＨＢＶ—ＤＮＡ阴转率，除治疗Ⅱ组在治疗结束时ＨＢｅＡｇ阴转率外．其余均有统计学意义。治疗组两种治疗方案无显著差别．对ＨＢｓＡｇ阴转无明显作用。两个用Ａｒａ—ＡＭＰ的治疗组均未出现严重毒副反应。

Abstract

90 patients with chroni c active or chroulc persi sten t hepatitis type B were divided into threegroupe at random。Patients in group one were treated with vidarabine monophosphate(Ara- AMP)and thymosin; patients in grroup two were treated with Ara-AMP and HB vaccine. While patientsin groups three served as control. By the end of 3months after t reatment

the rates of HBeAg frompositive to negative were 40%、 36.7%and 13.3%hgroup one

group two and group threerespectively

and the rates of HBV- DNA from pesitive to negative were 46.1%

48%and 12%ineach group respectively

and negative conversion rates of HBeAg and HBV-DNA in the twotreament groups were statistically significant exceptfor the negateve conversion rates of HBe Agof group two by the end of treatinent.HBsAg of three groups remained positive during the routineobservation period .The Lowering of ALT and AST seemed to be same effective in group one and group two

was not statisticdly significant.The side effect of Ara- AMP was minor in degree

andouly one patient felt severe headache.

关键词

单磷酸阿糖腺苷乙型肝炎免疫调节剂

Keywords

Vidarabine Monophosphatehepatitis BImmunomodulators

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

New strategies for the clearance of the surface antigen in chronic hepatitis B patients

CLINICAL ANALYSIS OF VIRAL HEPATITIS IN CHONGQING

Construction of a recombinant adenovirus vector containing HBX gene

Intrahepatic cholestasis of pregnancy diagnosis based on metabolic profiling of serum bile acid

Three years clinical observation on Telbivudine in the treatment of chronic hepatits B LIU Xiaoqin，ZHANG Dazhi，GUO Shuhua

Related Author

Huang Ailong

张定凤

秦波

范淳

贾小平

骆骅

周亚苏

et al

Related Institution

Institute for Viral Hepatitis,Key Laboratory of Molecular Biology on Infectious Diseases Founded by Ministry of Education,Chongqing Medical University

重庆医科大学第二医院肝炎研究所

Department of Biochemistry,College of Basic Medicine,Chongqing Medical University

芝加哥大学医学中心分子肿瘤研究室

重庆医科大学基础医学院生物化学教研室

⁰